Two Phase 3 Trials of Lebrikizumab for Moderate-to-Severe Atopic Dermatitis
Two Phase 3 Trials of Lebrikizumab for Moderate-to-Severe Atopic Dermatitis is a paper indexed in ScholarIQ from OpenAlex.
How many citations does Two Phase 3 Trials of Lebrikizumab for Moderate-to-Severe Atopic Dermatitis have?
Two Phase 3 Trials of Lebrikizumab for Moderate-to-Severe Atopic Dermatitis has 329 citations in the OpenAlex counts ScholarIQ stores.
When was Two Phase 3 Trials of Lebrikizumab for Moderate-to-Severe Atopic Dermatitis published?
Two Phase 3 Trials of Lebrikizumab for Moderate-to-Severe Atopic Dermatitis has 2023 year in the ScholarIQ index.
What is the open-access status of Two Phase 3 Trials of Lebrikizumab for Moderate-to-Severe Atopic Dermatitis?
Two Phase 3 Trials of Lebrikizumab for Moderate-to-Severe Atopic Dermatitis has closed oa status in the ScholarIQ index.
What is the DOI of Two Phase 3 Trials of Lebrikizumab for Moderate-to-Severe Atopic Dermatitis?
The DOI for Two Phase 3 Trials of Lebrikizumab for Moderate-to-Severe Atopic Dermatitis is on the source record.
What is the PMID of Two Phase 3 Trials of Lebrikizumab for Moderate-to-Severe Atopic Dermatitis?
The PMID for Two Phase 3 Trials of Lebrikizumab for Moderate-to-Severe Atopic Dermatitis is on the source record.
What is the OpenAlex record for Two Phase 3 Trials of Lebrikizumab for Moderate-to-Severe Atopic Dermatitis?
The OpenAlex for Two Phase 3 Trials of Lebrikizumab for Moderate-to-Severe Atopic Dermatitis is on the source record.